In addition, since CHD7 is thought to recruit cell type-specific enhancers to modulate transcription (Schnetz et al., 2009, 2010; Bajpai et al., 2010; Zentner et al., 2010), it is also possible that the clinical variability of the congenital anomalies in CHARGE syndrome might be due to alterations in transcription of tissue-specific genes normally regulated by CHD7 during development (Basson and van Ravenswaaij-Arts, 2015). The gene discussed is CHD7; the disease is CHARGE syndrome.